{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:40:01Z","timestamp":1759135201689,"version":"3.44.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"DOI":"10.7759\/cureus.93460","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:23:49Z","timestamp":1759134229000},"source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment"],"prefix":"10.7759","author":[{"given":"Idowu","family":"Olaogun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekenechukwu E","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Obumneme B","family":"Anyim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.73.2.257","article-title":"Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure","volume":"73","author":"Lee WH","year":"1986","unstructured":"Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986, 73:257-67. 10.1161\/01.cir.73.2.257","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis JG","year":"2013","unstructured":"Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013, 126:S1-42. 10.1016\/j.amjmed.2013.07.006","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14472","article-title":"Admission hyponatraemia as heart failure events predictor in patients with acute heart failure","volume":"10","author":"Sarastri Y","year":"2023","unstructured":"Sarastri Y, Zebua JI, Lubis PN, Zahra F, Lubis AC. Admission hyponatraemia as heart failure events predictor in patients with acute heart failure. ESC Heart Fail. 2023, 10:2966-72. 10.1002\/ehf2.14472","journal-title":"ESC Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier RW","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006, 355:2099-112. 10.1056\/NEJMoa065181","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogu\u00e9 HJ","year":"2000","unstructured":"Adrogu\u00e9 HJ, Madias NE. Hyponatremia. N Engl J Med. 2000, 342:1581-9. 10.1056\/NEJM200005253422107","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.02.095","article-title":"Vasopressin antagonism in heart failure","volume":"46","author":"Goldsmith SR","year":"2005","unstructured":"Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005, 46:1785-91. 10.1016\/j.jacc.2005.02.095","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam MA","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, et al.. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007, 297:1319-31. 10.1001\/jama.297.12.1319","journal-title":"JAMA"},{"key":"ref8","unstructured":"FDA Drug Safety Communication. FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. (2013). Accessed: June 5, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-limits-duration-and-usage-sa...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200307000-00004","article-title":"Treatment of symptomatic hyponatremia","volume":"326","author":"Decaux G","year":"2003","unstructured":"Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci. 2003, 326:25-30. 10.1097\/00000441-200307000-00004","journal-title":"Am J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.05.011","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines and the Heart Failure Society of America","volume":"68","author":"Yancy CW","year":"2016","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016, 68:1476-88. 10.1016\/j.jacc.2016.05.011","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray JJ","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, et al.. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012, 33:1787-847. 10.1093\/eurheartj\/ehs104","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade M","year":"2007","unstructured":"Gheorghiade M, Abraham WT, Albert NM, et al.. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007, 28:980-8. 10.1093\/eurheartj\/ehl542","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X15666190306111812","article-title":"Hyponatremia in heart failure: pathogenesis and management","volume":"15","author":"Rodriguez M","year":"2019","unstructured":"Rodriguez M, Hernandez M, Cheungpasitporn W, et al.. Hyponatremia in heart failure: pathogenesis and management. Curr Cardiol Rev. 2019, 15:252-61. 10.2174\/1573403X15666190306111812","journal-title":"Curr Cardiol Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-015-0082-5","article-title":"Hyponatremia during hospitalization and in-hospital mortality in patients hospitalized from heart failure","volume":"15","author":"Saepudin S","year":"2015","unstructured":"Saepudin S, Ball PA, Morrissey H. Hyponatremia during hospitalization and in-hospital mortality in patients hospitalized from heart failure. BMC Cardiovasc Disord. 2015, 15:88. 10.1186\/s12872-015-0082-5","journal-title":"BMC Cardiovasc Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22180","article-title":"Predictors of 30-day readmission in patients hospitalized with decompensated heart failure","volume":"36","author":"Hernandez MB","year":"2013","unstructured":"Hernandez MB, Schwartz RS, Asher CR, et al.. Predictors of 30-day readmission in patients hospitalized with decompensated heart failure. Clin Cardiol. 2013, 36:542-7. 10.1002\/clc.22180","journal-title":"Clin Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2010.00156.x","article-title":"Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism","volume":"16","author":"Rosner MH","year":"2010","unstructured":"Rosner MH, Ronco C. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism. Congest Heart Fail. 2010, 16:S7-14. 10.1111\/j.1751-7133.2010.00156.x","journal-title":"Congest Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm4050933","article-title":"Hyponatremia associated with heart failure: pathological role of vasopressin-dependent impaired water excretion","volume":"4","author":"Ishikawa SE","year":"2015","unstructured":"Ishikawa SE. Hyponatremia associated with heart failure: pathological role of vasopressin-dependent impaired water excretion. J Clin Med. 2015, 4:933-47. 10.3390\/jcm4050933","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00902.x","article-title":"Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure","volume":"66","author":"Funayama H","year":"2004","unstructured":"Funayama H, Nakamura T, Saito T, Yoshimura A, Saito M, Kawakami M, Ishikawa SE. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. 2004, 66:1387-92. 10.1111\/j.1523-1755.2004.00902.x","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients\u00a0with acute heart failure and\u00a0volume overload","volume":"69","author":"Konstam MA","year":"2017","unstructured":"Konstam MA, Kiernan M, Chandler A, et al.. Short-term effects of tolvaptan in patients\u00a0with acute heart failure and\u00a0volume overload. J Am Coll Cardiol. 2017, 69:1409-19. 10.1016\/j.jacc.2016.12.035","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13533","article-title":"Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study","volume":"8","author":"Shahim A","year":"2021","unstructured":"Shahim A, Hourqueig M, Donal E, et al.. Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study. ESC Heart Fail. 2021, 8:4243-54. 10.1002\/ehf2.13533","journal-title":"ESC Heart Fail"},{"key":"ref21","unstructured":"FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death. (2017). Accessed. September 28, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-limits-duration-and-usage-sa...."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.09.091","article-title":"Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction","volume":"103","author":"Rusinaru D","year":"2009","unstructured":"Rusinaru D, Buiciuc O, Leborgne L, Slama M, Massy Z, Tribouilloy C. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol. 2009, 103:405-10. 10.1016\/j.amjcard.2008.09.091","journal-title":"Am J Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S138535","article-title":"Hyponatremia in the elderly: challenges and solutions","volume":"12","author":"Filippatos TD","year":"2017","unstructured":"Filippatos TD, Makri A, Elisaf MS, Liamis G. Hyponatremia in the elderly: challenges and solutions. Clin Interv Aging. 2017, 12:1957-65. 10.2147\/CIA.S138535","journal-title":"Clin Interv Aging"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart\u00a0failure with reduced ejection\u00a0fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox TM","year":"2024","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, et al.. 2024 ACC expert consensus decision pathway for treatment of heart\u00a0failure with reduced ejection\u00a0fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024, 83:1444-88. 10.1016\/j.jacc.2023.12.024","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.08.083","article-title":"Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score","volume":"55","author":"O'Connor CM","year":"2010","unstructured":"O'Connor CM, Hasselblad V, Mehta RH, et al.. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010, 55:872-8. 10.1016\/j.jacc.2009.08.083","journal-title":"J Am Coll Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100217","article-title":"Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure","volume":"68","author":"Cyr PL","year":"2011","unstructured":"Cyr PL, Slawsky KA, Olchanski N, Krasa HB, Goss TF, Zimmer C, Hauptman PJ. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. Am J Health Syst Pharm. 2011, 68:328-33. 10.2146\/ajhp100217","journal-title":"Am J Health Syst Pharm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.643329","article-title":"Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial","volume":"15","author":"Chiong JR","year":"2012","unstructured":"Chiong JR, Kim S, Lin J, Christian R, Dasta JF. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ. 2012, 15:276-84. 10.3111\/13696998.2011.643329","journal-title":"J Med Econ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12783","article-title":"Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF)","volume":"7","author":"Ng TM","year":"2020","unstructured":"Ng TM, Grazette LP, Fong MW, et al.. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF). ESC Heart Fail. 2020, 7:1927-34. 10.1002\/ehf2.12783","journal-title":"ESC Heart Fail"},{"key":"ref29","unstructured":"Hyponatraemia. scenario: management. (2015). Accessed: September 28, 2025: https:\/\/cks.nice.org.uk\/topics\/hyponatraemia\/management\/management\/."},{"key":"ref30","unstructured":"Clinical Commissioning Policy. tolvaptan for hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone (SIADH) in patients requiring cancer chemotherapy. (2016). Accessed: September 28, 2025: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2016\/12\/clin-comm-pol-16051P.pdf."},{"key":"ref31","unstructured":"National Heart Failure Audit (NHFA). (2021). Accessed. June 5, 2025: https:\/\/www.nicor.org.uk\/national-cardiac-audit-programme\/heart-failure-audit-nhfa."},{"key":"ref32","unstructured":"National Institute for Health and Care Excellence Surveillance Programme. (2017). Accessed. June 20, 2025: https:\/\/www.nice.org.uk\/guidance\/cg187\/documents\/surveillance-review-proposal."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070132","article-title":"Vasopressin-receptor antagonists in heart failure","volume":"65","author":"Schweiger TA","year":"2008","unstructured":"Schweiger TA, Zdanowicz MM. Vasopressin-receptor antagonists in heart failure. Am J Health Syst Pharm. 2008, 65:807-17. 10.2146\/ajhp070132","journal-title":"Am J Health Syst Pharm"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12124","article-title":"Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project","volume":"4","author":"Pose A","year":"2017","unstructured":"Pose A, Almenar L, Gavira JJ, et al.. Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project. ESC Heart Fail. 2017, 4:130-7. 10.1002\/ehf2.12124","journal-title":"ESC Heart Fail"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13010140","article-title":"Management of hyponatremia in heart failure: practical considerations","volume":"13","author":"\u015eorodoc V","year":"2023","unstructured":"\u015eorodoc V, Asaftei A, Puha G, et al.. Management of hyponatremia in heart failure: practical considerations. J Pers Med. 2023, 13:140. 10.3390\/jpm13010140","journal-title":"J Pers Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002259","article-title":"Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials","volume":"8","author":"Felker GM","year":"2015","unstructured":"Felker GM, Mentz RJ, Adams KF, et al.. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail. 2015, 8:997-1005. 10.1161\/CIRCHEARTFAILURE.115.002259","journal-title":"Circ Heart Fail"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3810\/hp.2012.02.942","article-title":"Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials","volume":"40","author":"Dasta JF","unstructured":"Dasta JF, Chiong JR, Christian R., et al.. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract. 40:7-14. 10.3810\/hp.2012.02.942","journal-title":"Hosp Pract"},{"key":"ref38","article-title":"The SALT trials: effectiveness of tolvaptan in hyponatremia","volume":"355","author":"Schrier RW","year":"2006","unstructured":"Schrier RW, Gross P, Dineen R, et al.. The SALT trials: effectiveness of tolvaptan in hyponatremia. N Engl J Med. 2006, 355:2069-77.","journal-title":"N Engl J Med"},{"key":"ref39","unstructured":"Tolvaptan in British National Formulary (BNF). (2023). Accessed. September 28, 2025: https:\/\/bnf.nice.org.uk\/drugs\/tolvaptan\/."},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2012.03.956","article-title":"PDB35 evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the United States, based on the Salt-1 and Salt-2 trials","volume":"15","author":"Dasta JF","year":"2012","unstructured":"Dasta JF, Chiong JR, Christian R, Lin J. PDB35 evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the United States, based on the Salt-1 and Salt-2 trials. Value Health. 2012, 15:A176.","journal-title":"Value Health"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6870","article-title":"Lack of social care has cost the NHS 2.5 million bed days since last election, charity says","volume":"367","author":"Iacobucci G","year":"2019","unstructured":"Iacobucci G. Lack of social care has cost the NHS 2.5 million bed days since last election, charity says. BMJ. 2019, 367:l6870. 10.1136\/bmj.l6870","journal-title":"BMJ"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2020.12.027","article-title":"Bed-days and costs associated with the inpatient burden of healthcare-associated infection in the UK","volume":"114","author":"Manoukian S","year":"2021","unstructured":"Manoukian S, Stewart S, Graves N, et al.. Bed-days and costs associated with the inpatient burden of healthcare-associated infection in the UK. J Hosp Infect. 2021, 114:43-50. 10.1016\/j.jhin.2020.12.027","journal-title":"J Hosp Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/378487-revisiting-the-role-of-tolvaptan-in-the-management-of-hyponatraemia-in-acute-heart-failure-balancing-quality-of-life-and-cost-with-tolvaptan-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:23:54Z","timestamp":1759134234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/378487-revisiting-the-role-of-tolvaptan-in-the-management-of-hyponatraemia-in-acute-heart-failure-balancing-quality-of-life-and-cost-with-tolvaptan-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.93460","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,29]]}}}